Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Monoclonal Antibody
90%
Virus
82%
PROMETHEE
40%
Sin Nombre Virus
40%
Hantavirus
27%
Andes Virus
27%
Crimean-Congo Hemorrhagic Fever Virus (CCHFV)
25%
Fever
15%
In Vivo Half-life
13%
Humanization
13%
Multi-epitope
13%
Fc Effector
13%
Innovative Features
13%
In Vitro Toxicity
13%
Nairovirus
13%
Antibody-based
13%
Public Health
13%
New World Hantaviruses
13%
Advanced Development
13%
Oligoclonal Bands
13%
Genotypic Variation
13%
Antibody Response
13%
Viral Escape
13%
Virus Challenge
13%
Low Risk
13%
Protective Efficacy
13%
Preclinical Development
13%
Chimerism
13%
Convalescent
13%
High Risk
13%
Pathogen-specific
13%
Ebola Virus
13%
Antagonism
13%
Viral Particles
13%
Viral
13%
Infected Cells
13%
Zoonotic Disease
13%
Lead Molecule
13%
Viral Neutralization
13%
DNA-encoded Monoclonal Antibody
13%
Over 50
13%
Major Group
13%
Tissue Cross-reactivity
8%
Epitope Targeting
8%
Broadly Protective
8%
National Security
8%
NHPP Model
8%
Pan-ebolavirus
8%
Immunotherapeutics
8%
Cross-reactivity
5%
Immunology and Microbiology
Virus
100%
Monoclonal Antibody
85%
Sin Nombre Virus
51%
Hantavirus
51%
Human Monoclonal Antibody
46%
Crimean-Congo Hemorrhagic Fever Virus
36%
Andes Virus
34%
Ebola Virus
29%
Cross-Reactivity
17%
Nairovirus
17%
Genetic Variability
17%
Neutralization
17%
Virus Particle
17%
Infectious Agent
17%
Antibody Response
17%
Epitope
17%
Preclinical Study
17%
Zoonosis
12%
Zoonotic
5%